These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 31511065)

  • 1. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
    Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
    Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
    Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
    BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists.
    Druce I; Tawagi K; Shaw JLV; Ibrahim A; Lochnan H; Ong M
    Curr Oncol; 2022 Jul; 29(7):4665-4677. PubMed ID: 35877230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A; Bhat R; Cousins J
    Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab induced hypophysitis in an advanced RCC patient.
    Korkmaz Yilmaz M; Gulturk I; Tacar SY; Yilmaz M
    J Oncol Pharm Pract; 2022 Apr; 28(3):759-762. PubMed ID: 35006033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory hypotension due to Nivolumab-induced adrenal insufficiency.
    Tsukizawa Y; Kondo K; Ichiba T; Naito H; Mizuki K; Masuda K
    Nagoya J Med Sci; 2018 May; 80(2):285-288. PubMed ID: 29915446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab Induced Adrenal Insufficiency: Rare Side-effect of a New Anti-cancer Therapy - Immune-checkpoint Inhibitors.
    Rai M; Go M
    Cureus; 2020 Apr; 12(4):e7625. PubMed ID: 32399358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
    AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB; Bastholt L; Yderstræde K
    Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
    Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
    Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
    Mishima Y; Fukaishi T; Inase N; Isogai S
    Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis.
    Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
    Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis.
    Bando H; Yamamoto M; Urai S; Motomura Y; Sasaki Y; Ohmachi Y; Kobatake M; Tsujimoto Y; Oi-Yo Y; Suzuki M; Yamamoto N; Takahashi M; Fukuoka H; Iguchi G; Ogawa W
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38418395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
    Seki T; Yasuda A; Oki M; Kitajima N; Takagi A; Nakajima N; Miyajima A; Fukagawa M
    Tokai J Exp Clin Med; 2017 Sep; 42(3):115-120. PubMed ID: 28871578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.